Recruitment strategies in superiority trials in SLE: Lessons from the study of methotrexate in lupus erythematosus (SMILE)

Lupus

Volumn 8, Issue 8, 1999, Pages 606-611

  Ferland, Diane ^a,b   Fortin, Paul R ^a,b  

^a MCGILL UNIVERSITY HEALTH CENTRE   (Canada)

^b MONTREAL GENERAL HOSPITAL   (Canada)

Author keywords

Problems with recruitment; Recruitment strategies; SLE

Indexed keywords

FOLIC ACID ANTAGONIST; METHOTREXATE;

ARTICLE; CANADA; CLINICAL RESEARCH; CLINICAL TRIAL; HUMAN; PATIENT SELECTION; PHYSICIAN; PRIORITY JOURNAL; SYSTEMIC LUPUS ERYTHEMATOSUS;

CANADA; CLINICAL PROTOCOLS; DOUBLE-BLIND METHOD; FOLIC ACID; HUMANS; IMMUNOSUPPRESSIVE AGENTS; LUPUS ERYTHEMATOSUS, SYSTEMIC; METHOTREXATE; PATIENT SELECTION; RESEARCH DESIGN;

EID: 0032707975     PISSN: 09612033     EISSN: None     Source Type: Journal    
DOI: 10.1191/096120399680411371     Document Type: Article

References (30)

1. Tan E, Cohen A, Fries J et al. The 1982 revised criteria for the classification of systemic lupus erythematosus. Arthritis Rheum 1982; 25: 1271-1277.
2. Hochberg C. Updating the American College of Rheumatology revised criteria for the classification of systemic lupus erythematosus [letter]. Arthritis Rheum 1997; 40: 1725.
3. Dubois F. (ed.) Lupus Erythematosus. A review of the current status of discoid and systemic lupus erythematosus and their variants. 2nd ed revised. Los Angeles: USC Press, 1976.
4. Miescher P, Riethmuller D. Diagnosis and treatment of systemic lupus erythematosus. Sem Hematol 1965; 2: 1-28.
5. Davidson J, Graziano F, Grandone J et al. The use of methotrexate in steroid-resistant systemic lupus erythematosus. Arthritis Rheum 1988; 31: 612-615.
6. Wilke W, Krall P. Scheetz R et al. Methotrexate for systemic lupus erythematosus: a retrospective analysis of 17 unselected cases. Clin Exp Rheumatol 1991; 9: 581-587.
7. Wilson K, Katz J, Abeles M. The use of methotrexate in systemic lupus erythematosus. Arthritis Rheum 1991; 34: R39.
8. Wallace D. Cytotoxic drugs. In: Wallace D, Hahn B (eds.) Dubois Lupus Erythematosus. Philadelphia: Lea and Febinger, 1999, p 595.
9. Abud-Mendoza C, Sturbaum A, Vasquez-Compean R, Gonzalez-Amaro R. Methotrexate therapy in childhood systemic lupus erythematosus. J Rheum 1993; 20: 731-733.
10. Morelli S, Giodano M, De Marzio P et al Pulmonary arterial hypertension responsiveness to immunosuppressive therapy in systemic lupus erythematosus. Lupus 1993; 2: 367-369.
11. Fox D, McCune W. Immunosuppressive drug therapy of systemic lupus erythematosus. Rheum Dis Clin North Am 1994; 21: 265-299.
12. Walz-LeBlanc BAE, Dagenais P, Urowitz M, Gladman D. Methotrexate in systemic lupus erythematosus. J Rheumatol 1994; 21: 836-868.
13. Kipin Y, Liltlejohn G, Morand E. Methotrexate use in systemic lupus erythematosus. Lupus 1997; 6: 385-389.
14. Gansauge S, Breitbart A, Rinaldi N, Schwarz-Eywill M. Methotrexate in patients with moderate systemic lupus erythematosus (exclusion of renal and central nervous system disease). Ann Rheum Dis 1997; 56: 382-385.
15. Wise C, Vuyyuru S, Roberts W. Methotrexate in nonrenal lupus and undiffercntiated connective tissue disease - a review of 36 patients. J Rheumatol 1996; 23: 1005-1010.
16. Fink S, Kremer J. Successful treatment of interstitial lung disease in systemic lupus erythematosus with methotrexale. J Rheumatol 1995; 22: 967-969.
17. Gibinski K. Selection and recruitment of patients for biomedical experiments. In: Howard-Jones N, Bankowski Z (eds.) Medical Experimentation and the Protection of Human Rights. Geneva: Council for International Organizations of Medical Sciences; Sandoz Institute for Health and Socio-Economic Studies, 1979, pp 142-153.
18. Rosenstock I. Historical origins of the health belief model. Health Edu Monogr 1974; 2: 328-335.
19. Rimer B. Participant enrollment, participation and compliance in chemoprevention trials. In: Newell G, Hong W (eds.) The Biology and Prevention of Aerodigestive Tract Cancers. New York. Plenum Press, 1992, pp 111-117.
20. Edworthy S, Domazet N, Talavera R, Devins G. Illness instrusiveness: an intervening factor between symptoms and quality of life in patients with systemic lupus erythematosus. Arthritis Rheum 1998; 41: S262.
21. DaCosta D, Dobkin P, Fortin P et al. Illness intrusiveness mediates the relationship between disease activity and psychological distress in women with SLE [abstract]. 30th Laurentian Conference of Rheumatology May 28 and 29, 1999.
22. Spilker B. Patient recruitment. In: Spilker B (ed.) Guide to Clinical Trials. New York: Raven Press, 1992; pp 85-92.
23. Sullivan K, Hébert P, Logan J et al. What do physicians tell patients with end-stage COPD about intubation and mechanical ventilation. Chest 1996; 109: 258-264.
24. Pawlik-Plank D. Framing treatment options: a method to enhance informed consent. Clin Nurse Special 1994; 8: 174-178.
25. O'Connor A. Effects of framing and level of probability on patients' preferences for cancer chemotherapy. J. Clin Epidemiol 1989; 42: 119-126.
26. Teasdale K. Information and anxiety: a critical reappraisal. J Adv Nurs 1993; 18: 1125-1132.
27. O' Connor A, Pennie R, Dales R. Framing effects on expectations, decisions, and side effects experienced: the case of influenza immunization. J Clin Epidemiol 1996; 49: 1271-1276.
28. Shea S, Bigger JJ, Campion J et al. Enrollment in clinical trials: institutional factors affecting enrollment in the cardiac arrythmia suppression trial (CAST). Control Clin Trials 1992; 13: 466-486.
29. DeLuca S, Lorcuska L, Oberstar B et al Are we promoting true informed consent in cardiovascular clinical trials? J Cardiovasc Nurs 1995; 9: 54-61.
30. Polit D, Hungler B. Ethics and scientific research. In: Polit D, Hungler B (eds.) Nursing Research: Principles and Methods. Philadelphia: JB Lippincott Co, 1991, pp 29-47.